The GLP-1 Market Size is valued at USD 44.5 Bn in 2023 and is predicted to reach USD 95.4 Bn by the year 2031 at an 10.3% CAGR during the forecast period for 2024-2031.
The glucagon-like peptide-1 receptor (GLP1R) is a crucial target in treating type 2 diabetes and obesity, given its significant role in regulating blood sugar levels and appetite. GLP-1, a hormone produced in the gut, enhances insulin secretion from pancreatic beta cells in response to glucose, increases insulin expression, and reduces beta-cell apoptosis. It also lowers glucagon secretion, slows stomach emptying, promotes satiety, and improves glucose disposal in peripheral tissues. Medications known as GLP-1 agonists, including exenatide, liraglutide, and semaglutide, activate the GLP1R, effectively lowering blood sugar levels and facilitating weight loss in individuals with type 2 diabetes.
The global GLP-1 receptor agonist market is rapidly expanding due to the rising prevalence of type 2 diabetes and obesity, which have become major public health concerns. With diabetes diagnoses significantly increasing and obesity rates skyrocketing, there is a growing demand for effective treatments that manage blood sugar levels and promote weight loss. GLP-1 agonist medications, which target the GLP-1 receptor to regulate insulin, glucagon, and appetite, offer a promising therapeutic approach to these health challenges. As the prevalence of these metabolic disorders continues to rise, the GLP-1 receptor agonist market is set for substantial growth in the coming years.
Competitive Landscape
Some of the Key Players in GLP-1 Market:
- AstraZeneca
- Biolingus
- Boehringer Ingelheim
- D&D Pharmatech
- Eli Lilly
- Gmax Biopharm
- Hanmi Pharmaceutical
- Innogen
- Novo Nordisk
- PegBio
- Pfizer
- QL Biopharma
- Roche
- Sanofi
- Sciwind Biosciences
- Tonghua Dongbao Pharmaceutical
- Viking Therapeutics
- Vivani
- vTv Therapeutic
- Other Prominent Players
Market Segmentation:
The GLP-1 market is segmented by type of molecule, active compound used, type of glp-1 agonist drugs, type of agonist, route of administration, target indication. By type of molecule the market is segmented into biologics and small molecules, by active compound used market is categorized into dulaglutide, liraglutide, orforglipron, retatrutide, semaglutide, survodutide, tirzepatide and other active compounds. By type of glp-1 agonist drugs market is categorized into long-acting glp-1 agonist and short-acting glp-1 agonist. By type of agonist the market is single-agonist, dual-agonist and tri-agonist, by route of administration market is categorized into oral and parenteral, by target indication market is categorized into Alzheimer’s disease, non-alcoholic steatohepatitis, obesity, sleep apnea, type 2 diabetes.
Semaglutide Segment is Expected to Drive the GLP-1 Market
The semaglutide segment is a key driver of growth in the GLP-1 receptor agonist market due to its effectiveness and popularity. Marketed as Ozempic and Wegovy, semaglutide has proven highly effective in lowering blood sugar levels in type 2 diabetes patients and promoting significant weight loss in individuals with obesity. Its approval for obesity treatment has broadened its market appeal, especially as global obesity rates rise. Additionally, innovative formulations and administration methods, such as once-weekly injections and oral options, enhance patient convenience and adherence. Semaglutide also offers notable cardiovascular benefits, making it an attractive option for patients with type 2 diabetes and obesity who face increased heart disease risks.
The Obesity Segment is Growing at the Highest Rate in the GLP-1 Market.
The obesity segment is the fastest-growing area in the GLP-1 receptor agonist market due to several key factors. First, the global prevalence of obesity is rising, with over 40% of adults in the U.S. classified as clinically obese, driving demand for effective weight loss treatments like GLP-1 agonists. Additionally, regulatory approvals for drugs such as semaglutide (Wegovy) specifically for obesity treatment have expanded the patient population significantly. GLP-1 agonists have also shown strong efficacy in clinical trials, with patients achieving an average weight loss of 15-25%, further promoting rapid adoption. Moreover, increasing insurance coverage and affordability of these medications are enhancing patient access, facilitating their utilization in managing obesity.
Regionally, Asia-Pacific Led the GLP-1 Market.
The APAC region is leading the global GLP-1 receptor agonist market, characterized by rapid growth driven by countries such as China, Japan, and India. This expansion is fueled by a growing healthcare sector, a large target patient population, and significant unmet clinical needs for diabetes and obesity treatments. The rising prevalence of type 2 diabetes and obesity in these countries is increasing demand for effective GLP-1 agonist therapies. Additionally, major pharmaceutical companies are innovating and developing tailored solutions for the APAC market to meet these rising demands. Although specific market share data is limited, the APAC region is recognized as the fastest-growing and a key contributor to the overall GLP-1 receptor agonist market.
GLP-1 Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 44.5 Bn |
|
Revenue Forecast In 2031 |
USD 95.4 Bn |
|
Growth Rate CAGR |
CAGR of 10.3% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type of Molecule, Active Compound Used, Type of GLP-1 Agonist Drugs, Type of Agonist, Route of Administration, Target Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
|
Competitive Landscape |
AstraZeneca, Biolingus, Boehringer Ingelheim, D&D Pharmatech, Eli Lilly, Gmax Biopharm, Hanmi Pharmaceutical, Innogen, Novo Nordisk, PegBio, Pfizer, QL Biopharma, Roche, Sanofi, Sciwind Biosciences, Tonghua Dongbao Pharmaceutical, Viking Therapeutics, Vivani, vTv Therapeutic |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Geographic competitive landscape. |
|
Pricing and Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
